These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 11697839)

  • 1. Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.
    Ulrich-Pur H; Kornek GV; Fiebiger W; Gedlicka C; Raderer M; Lenauer A; Depisch D; Lang F; Pidlich J; Scheithauer W
    Ann Oncol; 2001 Sep; 12(9):1269-72. PubMed ID: 11697839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy.
    Scheithauer W; Kornek GV; Schuell B; Ulrich-Pur H; Penz M; Raderer M; Lang F; Schneeweiss B; Lenauer A; Depisch D
    Ann Oncol; 2001 May; 12(5):709-14. PubMed ID: 11432632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.
    Scheithauer W; Kornek GV; Brugger S; Ullrich-Pur H; Valencak J; Raderer M; Fiebiger W; Kovats E; Lang F; Depisch D
    Cancer Invest; 2002; 20(1):60-8. PubMed ID: 11853004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer.
    Hejna M; Köstler WJ; Raderer M; Tomek S; Brodowicz T; Scheithauer W; Wiltschke C; Zielinski CC
    Anticancer Drugs; 2000 Sep; 11(8):629-34. PubMed ID: 11081454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
    Masi G; Allegrini G; Cupini S; Marcucci L; Cerri E; Brunetti I; Fontana E; Ricci S; Andreuccetti M; Falcone A
    Ann Oncol; 2004 Dec; 15(12):1766-72. PubMed ID: 15550581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-Line Treatment of Advanced Colorectal Cancer with a Biweekly Oxaliplatin plus Irinotecan Combination Regimen.
    Schüll B; Kornek GV; Schmid K; Raderer M; Ulrich-Pur H; Fiebiger W; Schneeweiss B; Lenauer A; Depisch D; Scheithauer W
    Onkologie; 2002 Aug; 25(4):358-62. PubMed ID: 12232488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.
    Aparicio T; Desramé J; Lecomte T; Mitry E; Belloc J; Etienney I; Montembault S; Vayre L; Locher C; Ezenfis J; Artru P; Mabro M; Dominguez S;
    Br J Cancer; 2003 Oct; 89(8):1439-44. PubMed ID: 14562014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Raltitrexed and oxaliplatin in colorectal cancer: in vitro and in vivo study of a synergistic cytostatic combination].
    Schüll B; Scheithauer W
    Acta Med Austriaca; 2002; 29(4):124-31. PubMed ID: 12424937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC).
    Kouroussis C; Souglakos J; Mavroudis D; Papadouris S; Kakolyris S; Agelaki S; Kalbakis K; Panopoulos C; Vardakis N; Sarra E; Georgoulias V
    Am J Clin Oncol; 2002 Dec; 25(6):627-31. PubMed ID: 12478014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study.
    Rougier P; Lepille D; Bennouna J; Marre A; Ducreux M; Mignot L; Hua A; Méry-Mignard D
    Ann Oncol; 2002 Oct; 13(10):1558-67. PubMed ID: 12377643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
    Vasile E; Masi G; Fornaro L; Cupini S; Loupakis F; Bursi S; Petrini I; Di Donato S; Brunetti IM; Ricci S; Antonuzzo A; Chiara S; Amoroso D; Andreuccetti M; Falcone A
    Br J Cancer; 2009 Jun; 100(11):1720-4. PubMed ID: 19436300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
    Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
    Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
    Stathopoulos GP; Rigatos SK; Stathopoulos JG; Xynotroulas JP; Dimou E
    Am J Clin Oncol; 2005 Dec; 28(6):565-9. PubMed ID: 16317265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.
    Calvo E; Cortés J; Rodríguez J; Fernández-Hidalgo O; Rebollo J; Martín-Algarra S; García-Foncillas J; Martínez-Monge R; de Irala J; Brugarolas A
    Clin Colorectal Cancer; 2002 Aug; 2(2):104-10. PubMed ID: 12453325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients.
    Cals L; Rixe O; François E; Favre R; Merad L; Deplanque G; Laadem A; Juin P; Bereder JM; Bernardini D; Herait P
    Ann Oncol; 2004 Jul; 15(7):1018-24. PubMed ID: 15205194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer.
    Scheithauer W; Kornek GV; Raderer M; Ulrich-Pur H; Fiebiger W; Gedlicka C; Schüll B; Brugger S; Schneeweiss B; Lang F; Lenauer A; Depisch D
    J Clin Oncol; 2002 Jan; 20(1):165-72. PubMed ID: 11773166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-agent irinotecan as second-line weekly chemotherapy in elderly patients with advanced colorectal cancer.
    Rosati G; Cordio S
    Tumori; 2006; 92(4):290-4. PubMed ID: 17036518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
    Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
    Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
    Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.